pharmaphorum7m
Lilly's Alzheimer's drug gets UK nod but won't be NHS-funded
The UK medicines regulator approved Eli Lilly's Alzheimer's disease therapy Kisunla today, but the drug is too expensive to ...
Gazette and Herald8m
Donanemab trial patient: ‘I feel as normal as a 78-year-old can be’
A retired journalist who took part in the clinical trial for the new Alzheimer’s drug has described how he feels “as normal as a 78-year-old can be”. Peter Almond finished a trial for donanemab in ...
Salisbury Journal16m
Donanemab – what we know about the latest Alzheimer’s drug
Donanemab is a targeted antibody drug which slows down the early stages of Alzheimer’s. The drug, and another new drug for Alzheimer’s called lecanemab, have been billed as a huge step forward in ...
Eli Lilly’s Alzheimer’s drug donanemab rejected for NHS use
The U.K. watchdog declines to endorse Eli Lilly's Alzheimer's drug donanemab, citing lack of value for the NHS and ...
Anger as NHS patients told they WON'T get Alzheimer's drug donanemab
In a blow to tens of thousands of Brits, draft guidance by the NHS spending watchdog ruled the benefits of the drug are far ...
Eli Lilly Alzheimer’s Drug Rejected for NHS Use in England
Eli Lilly & Co’s Alzheimer’s drug won’t be made available for patients using England’s National Health Service, after the ...
NHS will not fund new drug to slow Alzheimer’s
A new drug that slows the pace of Alzheimer's disease is too expensive for too little benefit to be used on the NHS, the ...
Alzheimer’s wonder drug faces NHS block over cost
The most effective drug for Alzheimer’s will be blocked for use on the NHS on Wednesday. Regulators are expected to declare ...